8-K current report · filed Aug 6, 2026

PULSE BIOSCIENCES, INC. (PLSE) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1PLSE overview

Short answer

PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial and operational results announced for quarter ended June 30, 2026.

PULSE BIOSCIENCES, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial and operational results announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive results
  • Disclosure not deemed filed under Exchange Act Section 18, limiting liability and incorporation implications

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $434,000, while controlled commercial launch keeps near-term sales limited
  • GAAP net loss widened to $24.7 million from $19.2 million, driven by heavier clinical and compensation spending
  • Cash $101.6 million after $46.8 million ATM proceeds, with an additional $10.7 million raised after quarter-end
  • NANOPULSE-AF surpassed 82 evaluable patients, with enrollment target increased by 19 to 164
  • Key catalysts include early Q4 2026 catheter enrollment completion and potential CE Mark approvals by mid-2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PULSE BIOSCIENCES, INC. 8-K filings

Get the next PLSE 8-K as it lands

Follow PLSE for push alerts, or ask the research agent what this filing means.